Gilead Sciences, Inc. vs NetEase Inc — how do they compare? Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B), while NetEase Inc trades at $123.19 (market cap $82.75B). The key difference: Gilead Sciences, Inc. is far larger — about 2× NetEase Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | NTES | |
|---|---|---|
Market Cap | $168.35B | $82.75B |
Sector | Health | Media |
52-Week High | $155.80 | $159.34 |
52-Week Low | $110.56 | $109.26 |
Enterprise Value | $191.42B | $59.05B |
Dividend Yield | 2.42% | 2.36% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →